Vitamin D, Gut Microbiota, and Cardiometabolic Diseases-A Possible Three-Way Axis

Int J Mol Sci. 2023 Jan 4;24(2):940. doi: 10.3390/ijms24020940.

Abstract

Metabolic syndrome (MetSyn) is a precursor for several cardiometabolic diseases such as obesity, type-2 diabetes mellitus (T2DM), and cardiovascular diseases. Emerging evidence suggests that vitamin D deficiency links to cardiometabolic diseases through microbiota. A combination of poor vitamin D status and dysbiosis may contribute to the progression of cardiometabolic diseases. Therefore, in this review, we present the relationship among vitamin D, microbiota, and cardiometabolic diseases with a focus on MetSyn. We searched major databases for reports on vitamin D, microbiota, and MetSyn until June 2022. We reviewed 13 reports on the relation between vitamin D and MetSyn (6 randomized controlled and 7 cross-sectional studies) and 6 reports on the effect of vitamin D on the gut microbiome. Adequate vitamin D status has a beneficial effect on gut microbiota, therefore preventing the progression of MetSyn. Further, well-controlled studies are needed for a better understanding of the mechanisms of action involving vitamin D and microbiota in the pathogenesis of cardiometabolic diseases.

Keywords: 25-hydroxyvitamin D; diabetes; gut microbiome; metabolic syndrome; microbiota; obesity; type-2 diabetes; vitamin D.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases* / complications
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2* / etiology
  • Dysbiosis / complications
  • Gastrointestinal Microbiome*
  • Humans
  • Metabolic Syndrome* / complications
  • Vitamin D / metabolism
  • Vitamins

Substances

  • Vitamin D
  • Vitamins

Grants and funding

This research received no external funding.